PROFIT AND LOSS | 9M 2023 | 9M 2022 | Growth as reported | Growth at CER* |
DKK million | ||||
Net sales | 166,398 | 128,862 | 29% | 33% |
Operating profit | 75,808 | 57,722 | 31% | 37% |
Net profit | 61,720 | 41,933 | 47% | N/A |
Diluted earnings per share (in DKK) | 13.71 | 9.21 | 49% | N/A |
* CER: Constant exchange rates (average 2022). |
Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the sales growth in the first nine months of 2023, which is reflecting that more people than ever are benefiting from our innovative diabetes and obesity treatments. Within R&D, we are pleased with the decision to stop the FLOW kidney outcomes trial early as semaglutide demonstrated a benefit in people with type 2 diabetes and chronic kidney disease. The acquisition of ocedurenone for the treatment of cardiovascular disease supports our aspiration of establishing a presence in other serious chronic diseases with high unmet medical needs."
On 2 November 2023 at 13.00 CET, corresponding to 08.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
Contacts for further information | |
Media: | |
Ambre James-Brown +45 3079 9289 This email address is being protected from spambots. You need JavaScript enabled to view it. | Elizabeth DeLuca (US) +1 609 580 9868 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Investors: | |
Daniel Muusmann Bohsen +45 3075 2175 This email address is being protected from spambots. You need JavaScript enabled to view it. | David Heiberg Landsted +45 3077 6915 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Jacob Martin Wiborg Rode +45 3075 5956 This email address is being protected from spambots. You need JavaScript enabled to view it. | Mark Joseph Root (US) +1 848 213 3219 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Sina Meyer +45 3075 6656 This email address is being protected from spambots. You need JavaScript enabled to view it. | Frederik Taylor Pitter +45 3075 8259 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$131.14 |
Daily Change: | 0.25 0.19 |
Daily Volume: | 2,569,667 |
Market Cap: | US$443.250B |
July 10, 2024 June 24, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB